EUVIMEDEUVIMED entdecken
Open Access

Safety and effectiveness of drug-coated devices in chronic limb-threatening ischaemia: a nationwide analysis

Maxime Dubosq-Lebaz, Siling Li, Yann Gouëffic, Hyeok-Hee Lee, Joseph M Kim, Jonathan Sobocinski, Christian-Alexander Behrendt, Osamu Iida, Eric A Secemsky

EuroIntervention · 2026

DOI: 10.4244/eij-d-25-00769 ↗

Kurz gefasst

Fachartikel in der Zeitschrift EuroIntervention, 2026. Verfasst von Maxime Dubosq-Lebaz und 8 weiteren Autor:innen. Beteiligte Einrichtung: Richard A. and Susan F. Smith Center for Outcomes Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. Hauptthemen laut MEDLINE: Drug-Eluting Stents, Angioplasty, Balloon, Ischemia, Peripheral Arterial Disease. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Endovascular therapy is a cornerstone for chronic limb-threatening ischaemia (CLTI), yet the optimal device strategy remains uncertain. AIMS: Our objective was to compare the clinical and economic outcomes between plain balloon angioplasty±bare metal stents (PBA±BMS), drug-coated balloons (DCBs)±BMS, and drug-eluting stents (DES) in a national real-world CLTI cohort. METHODS: Medicare beneficiaries aged ≥66 years who underwent femoropopliteal revascularisation for CLTI between 2016 and 2023 were included. Patients were grouped by index device. Outcomes included a composite of all-cause mortality or major amputation, as well as major adverse limb events (MALE) and reintervention. Patients were followed from the index procedure until death, loss to follow-up, or the end of the study period. Time-to-event and cost outcomes were analysed using multivariable Cox and gamma regression models, respectively. RESULTS: Among 108,304 CLTI patients, 52.5% received PBA±BMS, 30.7% DCBs, and 16.8% DES. At 2 years, the composite outcome occurred in 50.54% (PBA±BMS), 43.08% (DCB±BMS), and 43.71% (DES); at 5 years, it occurred in 75.69%, 71.19%, and 71.71%, respectively. Compared with PBA±BMS, DCB±BMS (hazard ratio [HR] 0.92, 95% confidence interval [CI]: 0.90-0.93) and DES (HR 0.93, 95% CI: 0.92-0.95) were associated with a lower risk of the composite outcome. DCBs were associated with reduced major amputation (HR 0.87, 95% CI: 0.84-0.91), mortality (HR 0.93, 95% CI: 0.91-0.94), MALE (HR 0.96, 95% CI: 0.94-0.98), and reintervention (HR 0.97, 95% CI: 0.96-0.99) compared with PBA±BMS. The proportion of BMS use was 10.1% in the PBA±BMS group and 3.1% in the DCB±BMS group. CONCLUSIONS: In this national CLTI cohort, drug-coated devices were associated with reduced amputation and mortality. Data from this study suggest that DCBs may offer consistent benefit without increased costs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug-Eluting StentsAngioplasty, BalloonIschemiaPeripheral Arterial DiseaseChronic Limb-Threatening IschemiaHumansMaleAgedFemaleTreatment OutcomeAged, 80 and overUnited StatesAmputation, SurgicalCoated Materials, BiocompatibleLimb SalvageChronic Disease

Substanzen

Coated Materials, Biocompatible

Autor:innen und Institutionen

  • Richard A. and Susan F. Smith Center for Outcomes Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
  • Department of Vascular and Endovascular Surgery, Groupe Hospitalier Paris St Joseph, Paris, France.
  • Division of Vascular and Endovascular Surgery, Institut Coeur Poumon, CHU Lille, Lille, France.
  • Department of Vascular and Endovascular Surgery, Asklepios Clinic Wandsbek, Asklepios Medical School, Hamburg, Germany and German Institute for Vascular Research, Berlin, Germany.
  • Cardiovascular Division, Osaka Keisatsu Hospital, Osaka, Japan.

Zitieren

APA

Dubosq-Lebaz, M., Li, S., Gouëffic, Y., Lee, H. H., Kim, J. M., Sobocinski, J., Behrendt, C. A., Iida, O., & Secemsky, E. A. (2026). Safety and effectiveness of drug-coated devices in chronic limb-threatening ischaemia: a nationwide analysis. EuroIntervention. https://doi.org/10.4244/eij-d-25-00769

Vancouver

Dubosq-Lebaz M, Li S, Gouëffic Y, Lee HH, Kim JM, Sobocinski J, et al. Safety and effectiveness of drug-coated devices in chronic limb-threatening ischaemia: a nationwide analysis. EuroIntervention. 2026. doi:10.4244/eij-d-25-00769

BibTeX
@article{DubosqLebaz2026,
  author = {Dubosq-Lebaz, Maxime and Li, Siling and Gouëffic, Yann and Lee, Hyeok-Hee and Kim, Joseph M and Sobocinski, Jonathan and Behrendt, Christian-Alexander and Iida, Osamu and Secemsky, Eric A},
  title = {Safety and effectiveness of drug-coated devices in chronic limb-threatening ischaemia: a nationwide analysis},
  journal = {EuroIntervention},
  year = {2026},
  doi = {10.4244/eij-d-25-00769}
}
Kostenlos starten →